Roche agreed to a collaboration and licensing deal with Freenome worth potentially more than $200 million to commercialize Freenome’s blood-based cancer screening tests outside the U.S.; Roche also invested $75 million of the package as equity. Under the agreement, Roche gains rights to develop kit-based, distributed versions of Freenome tests for ex‑US markets and access to cohorts and technologies to accelerate test development. Separately, Roche showcased early data for its Axelios 1 sequencing-by‑expansion (SBX) platform at the Association for Molecular Pathology, reporting tumor/normal concordance with Illumina NovaSeq and highlighting faster throughput and automation for cancer genomics and ctDNA work. Roche presented Axelios 1 as a potential high-speed option for oncology diagnostics and ctDNA mutation plus methylation detection. Taken together, the commercial tie-up and platform development signal Roche’s push to couple novel screening assays with proprietary sequencing and kit capabilities to scale cancer-detection tools globally.